News & Stories
See the latest news about CMT drug development and read stories from the CMT community that highlight why we must deliver treatments and cures during our lifetime.
CMTRF’s Dr. Grace Pavlath on new results in gene therapy research for CMT1X
There’s a lot of excitement around gene-targeted therapies for their ability to treat the underlying root cause of various diseases and result in life altering outcomes. The neuromuscular disease field has recently seen the FDA approval of gene-targeted therapies for...
CMT1A Research Update
CMT1A is caused by a duplication of the PMP22 gene leading to overexpression of the PMP22 protein and failure of the Schwann cells to produce myelin (the insulation of the nerve) well. Without proper myelination, the nerves don’t send signals quickly or strongly,...
CMT1B project is funded & ready for take off!
Paving pathways for mission critical projects CMT Research Foundation is partnering with Dr. Maurizio D’Antonio of I.R.C.C.S. Ospedale San Raffaele, in Milan, Italy to fund the lab’s research of Myelin Protein Zero (MPZ), the gene associated with CMT1B. Dr....
New research efforts by Neurogene, give hope to patients suffering with an ultra-rare type of CMT: CMT4J
Neurogene, a leading company developing genetic medicines for people with rare, devastating neurological diseases, announced today that it is recruiting patients for a natural history study for CMT4J. "Key data now being collected to support endpoint assessment for...
Is “Disease-In-A-Dish” in Combination with Animal Models A Faster Track to a Cure for CMT?
From time to time the leadership of CMTRF will explore the challenges of finding treatments and a cure for CMT. To the extent we are able, we will try to overcome these obstacles to accelerate successful CMT research. Treatment of diseases, especially rare diseases...
Partnerships and Priorities: The Pathway to CMT Results
From time to time the CMT Research Foundation will examine the impediments to finding a cure for CMT. As the Chairman of a nonprofit foundation whose ONLY mission is to fund research that will lead to a cure for Charcot-Marie-Tooth disease (CMT), I am often...
New Evidence for Gene Replacement in a Mouse Model of Charcot-Marie-Tooth Disease
In an article published yesterday in Neurology Today, Dr. Kleopa demonstrated that gene replacement could be a viable treatment for recessive forms of CMT. CMT type 4C is a demyelinating disease, and this treatment both decreased the number of unmyelinated fibers and...
CMTRF investigates a gene therapy program for CMT1A
CMT Research Foundation Partners with Cyprus Institute for Neurology and Genetics’ Kleopas Kleopa to Launch Study of Possible Gene Therapy for CMT1A This is the second major investment by CMTRF. ATLANTA (January 16, 2019) The newly launched CMT Research Foundation...
CMTRF Inks Milestone-Driven Partnership with AcuraStem to Repurpose Established Drugs for the Treatment of CMT
Focus will be on expansion of AcuraStem’s patient-based discovery platform, iNeuroRx™, to leverage patient neurons and advanced informatics technology to identify promising drugs ATLANTA (December 20, 2018) The newly launched CMT Research Foundation (CMTRF), a...
Is there a connection between CMT1X and Multiple Sclerosis?
A recent study by Georgios Koutis et al at the National and Kapodistrian University of Athens recently published a paper in The Journal of Neurology, Neurosurgery and Psychiatry suggesting emerging evidence of a connection between CMTX1 and Multiple Sclerosis (MS)....
Important Research News Announcements
- Genomic Studies in Charcot-Marie-Tooth Disease July 31, 2024
- Charcot-Marie-tooth disease type 2A: An update on pathogenesis and therapeutic perspectives March 5, 2024
- Accelerate Clinical Trials in CMT (ACTCMT) Study March 1, 2024
- Creation of a Schwann Cell Gene Regulatory Network February 29, 2024
- Activation of XBP1s attenuates disease severity in models of proteotoxic Charcot-Marie-Tooth type 1B [Preprint] February 2, 2024
NEWSLETTER SIGNUP
Stay up to date on new CMT research, treatments and clinical trials
Address
4062 Peachtree Road
Suite A209
Atlanta, GA 30319
Phone Number
404.806.7180
Media Inquiries
© 2024 CMT Research Foundation | Privacy Policy